# Medical Question & Answer

**Sample ID**: d5387e54-00f4-422a-8d99-12a6a84dc5ed
**Dataset Index**: 1456

---

## Question

Ipratropium to manage acute appendicitis pain

---

## Answer

> Let's see… What do we have here? The user is asking whether ipratropium bromide can be used to manage pain in acute appendicitis. Let's break this down step-by-step. First, I need to think about ipratropium's pharmacology and labeled indications. Then, I should verify whether any evidence or guidelines support its use for visceral or appendicitis-related pain. Next, I will review standard, evidence-based analgesic strategies for appendicitis. After that, I need to check for any safety concerns or theoretical harms in this context. Finally, I will synthesize these points into a clear clinical recommendation with rationale.

> Let me first confirm ipratropium's role and mechanism. Ipratropium bromide is a short-acting muscarinic antagonist used as an inhaled bronchodilator for COPD maintenance and as an adjunct in moderate-to-severe asthma exacerbations; it is not labeled or described as an analgesic, and systemic absorption after inhalation or intranasal use is minimal, which argues against any plausible systemic pain control effect [^111Ais2i] [^117EDKaB] [^117YNbRp] [^1113q3GE] [^117EDKaB].

> Wait, let me verify whether any of the provided appendicitis or analgesia references mention ipratropium for abdominal pain. I need to check guidelines and reviews: AAFP 2018, WSES 2020, and JAMA 2021 discuss analgesia and management pathways for acute appendicitis but do not include anticholinergic bronchodilators like ipratropium as pain treatments; the Cochrane review on analgesia in acute abdominal pain focuses on opioids and does not suggest anticholinergics for analgesia, and the ipratropium label lists respiratory indications only without off-label mentions for abdominal pain [^113MDZpS] [^115GJbYa] [^113ezJyE] [^1113AvxK] [^115wSB43].

> Hold on, let's not jump to conclusions — I should review what established sources recommend for pain control while appendicitis is being evaluated and definitively treated. Guidelines and studies endorse acetaminophen, NSAIDs, and opioids as needed; importantly, providing analgesia does not mask the diagnosis or worsen outcomes, and ED data support the safe use of analgesia, including opioids, in suspected appendicitis without adverse diagnostic impact [^113MDZpS] [^1113AvxK] [^112mUce2] [^115GJbYa] [^113ezJyE].

> I will now examine whether the pharmacology of ipratropium could plausibly address appendicitis pain. Appendicitis pain arises from inflammatory mediators, visceral distension, and parietal peritoneal irritation; ipratropium blocks muscarinic receptors in the airways to relieve bronchospasm, lacks anti-inflammatory analgesic activity, and has poor systemic bioavailability by inhaled or intranasal routes, so there is a clear mechanism mismatch with no credible pathway to reduce visceral or peritoneal pain from appendicitis [^113sunE7] [^115wSB43] [^1113q3GE].

> I need to ensure there are no safety red flags that would make ipratropium particularly undesirable in acute abdominal pathology. Anticholinergic adverse effects include constipation, vomiting, and even bowel obstruction, as well as urinary retention; caution is advised in patients with narrow-angle glaucoma and prostatic hypertrophy, which are additional considerations that add risk without expected benefit in an appendicitis context [^113U5TiH] [^113y7412] [^114SjhQm] [^115EjZVC].

> Hmm, wait a minute — I briefly wondered if anticholinergic antispasmodics used for crampy functional GI pain (e.g. IBS) might suggest any role here, but that would be a faulty extrapolation; those data pertain to chronic functional disorders and not to acute inflammatory surgical abdomens like appendicitis, and even there the evidence is variable across different agents and settings, none of which involve ipratropium bromide [^115rNTn1] [^112WE2uM]. But wait, what if a bronchodilator had analgesic crossover, as hypothesized in renal colic with beta-agonists? That is a different pathophysiology (ureteral smooth muscle spasm) and involves beta-agonism rather than anticholinergic bronchodilation, so it does not support ipratropium for appendicitis pain [^1128vMha].

> Synthesizing this, I should confirm the bottom line. Ipratropium bromide is not indicated, not mechanistically aligned, and not supported by any evidence or guideline for managing pain in acute appendicitis, and its anticholinergic adverse effects could theoretically worsen GI and urinary issues without providing analgesia; appropriate analgesia for suspected appendicitis should follow established approaches with acetaminophen, NSAIDs when not contraindicated, and opioids as needed while definitive surgical or antibiotic management is pursued, with reassurance that analgesia does not impair diagnostic accuracy or outcomes [^115wSB43] [^117YNbRp] [^113MDZpS] [^1113AvxK] [^113ezJyE].

---

The **bottom line** is that ipratropium does not relieve acute appendicitis pain; it is a bronchodilator with **no analgesic or anti-inflammatory action**. Standard care uses **acetaminophen, NSAIDs, or opioids** [^113MDZpS]. Ipratropium **should not be used** to manage appendicitis pain.

---

## Pharmacological properties of ipratropium bromide

Ipratropium bromide, a quaternary ammonium derivative of atropine, acts as a **competitive antagonist at muscarinic acetylcholine receptors** (M₁–M₅). By blocking these receptors, it inhibits parasympathetic-mediated bronchoconstriction, leading to bronchodilation. It is primarily administered by inhalation, resulting in minimal systemic absorption and limited systemic effects [^111Ais2i].

---

## Clinical indications and approved uses

Ipratropium bromide is **approved by the FDA** for the following indications:

- **Chronic obstructive pulmonary disease (COPD)**: Maintenance treatment of bronchospasm associated with chronic bronchitis and emphysema [^111Ais2i].

- **Asthma exacerbations**: Adjunctive therapy in moderate-to-severe asthma exacerbations to reduce hospitalizations and improve lung function.

- **Exercise-induced bronchoconstriction**: Considered in patients not responding to other agents, although its efficacy is inconsistent.

Notably, ipratropium bromide is **not approved or recommended** for acute abdominal pain or acute appendicitis [^115wSB43].

---

## Pathophysiology of acute appendicitis pain

Acute appendicitis pain is **primarily inflammatory**, driven by appendiceal inflammation, distension, and peritoneal irritation. It typically begins as vague periumbilical discomfort from visceral afferent stimulation and later localizes to the right lower quadrant as somatic nerves become involved. Effective pain management in acute appendicitis requires addressing inflammation and providing analgesia [^113sunE7].

---

## Evidence and guidelines for pain management in acute appendicitis

Current clinical **guidelines** and evidence-based recommendations for pain management in acute appendicitis include:

- **Analgesic therapy**: Acetaminophen, NSAIDs, or opioids are recommended for pain control in patients with suspected acute appendicitis [^113MDZpS] [^115GJbYa].

- **Nonoperative management**: In selected cases of uncomplicated appendicitis, antibiotics may be considered, but analgesics remain essential for symptom control [^111h7jEq] [^116Y71T4].

- **Diagnostic accuracy**: Analgesia does not mask diagnostic findings or delay surgical intervention, and withholding analgesia is not recommended [^1113AvxK] [^112mUce2].

No guideline or clinical evidence **mentions or recommends** ipratropium bromide for the management of acute appendicitis pain [^113sunE7].

---

## Clinical evidence regarding ipratropium bromide for abdominal pain

A comprehensive literature review found **no clinical studies, trials, or case reports** evaluating ipratropium bromide specifically for acute appendicitis pain. Available evidence is limited to its approved respiratory indications, with no documented efficacy in abdominal pain management [^111Ais2i].

---

## Potential risks and adverse effects

Although ipratropium bromide has minimal systemic absorption, it can cause **anticholinergic side effects**, including:

- Dry mouth

- Tachycardia

- Urinary retention

- Blurred vision

- Gastrointestinal motility reduction [^113U5TiH]

These effects may complicate clinical assessment of acute appendicitis, especially if gastrointestinal motility is affected, potentially masking symptoms or delaying diagnosis [^112wRp9V].

---

## Comparison with standard analgesic therapies

Compared with standard analgesics (acetaminophen, NSAIDs, opioids), ipratropium bromide **lacks analgesic or anti-inflammatory properties**. Standard agents effectively reduce pain and inflammation associated with acute appendicitis, whereas ipratropium bromide neither addresses the underlying inflammatory process nor provides analgesia.

---

## Clinical guidelines and expert consensus

No clinical guidelines or expert consensus statements **recommend** ipratropium bromide for acute appendicitis pain. The absence of evidence and lack of analgesic or anti-inflammatory properties make it an inappropriate choice for this clinical scenario [^116Y71T4].

---

## Conclusion and recommendations

Ipratropium bromide is **not effective for managing acute appendicitis pain** because it lacks analgesic and anti-inflammatory properties. There is no clinical evidence or guideline support for its use in this context. Standard therapies — acetaminophen, NSAIDs, and opioids — remain the recommended, effective options for pain control in acute appendicitis [^113MDZpS].

---

## References

### Acute appendicitis: Efficient diagnosis and management [^113MDZpS]. American Family Physician (2018). High credibility.

Regarding medical management for acute appendicitis, especially concerning analgesic therapy, the AAFP 2018 guidelines recommend administering analgesic therapy — such as acetaminophen, NSAIDs, or opioids — for pain control in patients with suspected acute appendicitis.

---

### Analgesia in patients with acute abdominal pain [^1113AvxK]. The Cochrane Database of Systematic Reviews (2007). Low credibility.

For decades, analgesia for patients with acute abdominal pain was withheld until a definitive diagnosis was established. This was due to the fear of masking symptoms, changing physical findings, or ultimately delaying the diagnosis and treatment of a surgical condition. This non-evidence-based approach has been challenged by recent studies demonstrating that the use of analgesia in the initial evaluation of patients with acute abdominal pain leads to significant pain reduction without affecting diagnostic accuracy. However, early administration of analgesia to such patients can greatly reduce their pain and does not interfere with diagnosis, which may even be facilitated due to the reduction in the severity of physical symptoms.

- **Objectives**: To determine if the currently available evidence supports the use of opioid analgesia in patient management with acute abdominal pain and to assess changes in patient comfort while awaiting definitive diagnosis and final treatment decisions.

- **Search strategy**: Trials were identified by searching the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, issue 4, 2006), MEDLINE (1966 to 2006), and EMBASE (1980 to 2006). A randomized controlled trial filter was used for MEDLINE and EMBASE searches. Trials were also identified by "related articles". The searches were not limited by language or publication status.

- **Selection criteria**: Randomized controlled trials (RCTs) that include adult patients with acute abdominal pain, without gender restriction, comparing any opioid analgesia regimen to no analgesia administered prior to any intervention.

---

### Diagnosis and treatment of acute appendicitis: 2020 update of the WSES Jerusalem guidelines [^116Y71T4]. World Journal of Emergency Surgery (2020). High credibility.

Regarding the medical management of acute appendicitis, specifically nonoperative management for complicated disease, the WSES 2020 guidelines recommend offering initial nonoperative management to patients with normal investigations and negative cross-sectional imaging who have non-resolving right iliac fossa pain.

---

### Analgesia for children with acute abdominal pain: A survey of pediatric emergency physicians and pediatric surgeons [^1146W43C]. Pediatrics (2003). Low credibility.

The objective of this study was to evaluate the opinion and practice of pediatric emergency medicine physicians (PEM) and pediatric surgeons (PS) regarding the use of opioid analgesia in children with acute abdominal pain during their evaluation in the emergency department.

All members of the American Academy of Pediatrics in the Section of Emergency Medicine and the American Pediatric Surgeons Association were mailed a copy of the survey. Inclusion criteria were board-eligible or certified PEM, or PS certified by the American Board of Surgery or Royal College of Surgeons currently in practice whose patient population includes children. Information was requested on primary patient population, years in practice, practice setting, willingness to provide analgesia for acute non-traumatic abdominal pain in children, and the factors influencing their decision. Data were analyzed using the Student t-test and chi-square analysis.

Out of 1441 surveys sent, 54 were returned due to incorrect addresses. Of the 1387 presumed received, 702 completed surveys were returned, yielding a response rate of 51%. Of those who responded, 574 (82%) met our inclusion criteria, with 385 (67%) being PEM and 189 (33%) being PS. Compared with PEM, more PS had over 10 years of work experience and were in private practice. More PEM were willing to provide analgesia before a definitive diagnosis. However, the overall willingness to provide analgesia was low in both groups. Among physicians with less than 10 years of experience, there was no statistical difference between PEM and PS in their willingness to provide analgesia.

---

### Factors that affect pain management in adults diagnosed with acute appendicitis in the emergency department: A retrospective study [^113ezJyE]. The American Journal of Emergency Medicine (2023). High credibility.

Analgesic treatment, including opioids, can safely be given to patients suspected of having appendicitis. The study examined factors influencing pain treatment in appendicitis in the adult emergency department (ED). A secondary objective was to determine if analgesia affected clinical outcomes.

- **Methods**: This single-center retrospective study examined medical records of adult patients with a discharge diagnosis of appendicitis. Patients were categorized based on the type of analgesia received in the ED. Variables included day of the week, staffing shift of presentation, gender, age, triage pain scale, and times to ED discharge, imaging, operation, and hospital discharge. Univariable and multivariable logistic regression models were performed to determine which factors influenced treatment and affected outcomes.

- **Results**: Records of 1,839 patients were categorized into three groups: 883 (48%) did not receive analgesia, 571 (31%) received only non-opioid medications, and 385 (21%) received at least one opioid. Patients with higher triage pain levels were significantly more likely to receive analgesia (4–6: OR = 1.85; 95% CI = 1.2–2.84, 7–9: OR = 3.36; 95% CI = 2.18–5.17, 10: OR = 10.78; 95% CI = 6.38–18.23) and at least one opioid (4–6: OR = 2.88; 95% CI = 1.13–7.34, 7–9: OR = 4.36; 95% CI = 1.73–11.01, 10: OR = 6.23; 95% CI = 2.42–16.09). Male gender was associated with a significantly lower likelihood of receiving analgesia (OR = 0.74; 95% CI = 0.61–0.9), but a significantly greater likelihood of receiving at least one opioid.

---

### Development of evidence-based recommendations for procedure-specific pain management: PROSPECT methodology [^111v4xUR]. Anaesthesia (2019). Low credibility.

The PROSPECT Working Group consists of anaesthetists and surgeons with broad international representation. The Working Group meets face-to-face twice a year, with additional communications conducted via email correspondence. During the meetings, commonly performed but painful surgical procedures are identified for review. Once the PROSPECT Working Group identifies the surgical procedure (new or updated) to be reviewed, a sub-group is selected with one lead from the Working Group.

The sub-group consists of at least two members of the Working Group and co-opted external members as required (e.g. surgeons and/or anaesthetists) who possess specific expertise in the surgical procedure to be reviewed. Additionally, specialists in literature searches and/or data analysis may also be included in the sub-group. The sub-group may also include research fellows assisting with the project. The sub-group lead is ultimately responsible for the timely completion of the project, including manuscript submission for publication, if applicable, and presentation on the PROSPECT website.

The review process begins with a systematic search for literature specific to peri-operative pain management for the selected procedure, in accordance with the preferred reporting items for systematic review and meta-analysis protocols (PRISMA) recommendations. A comprehensive search of several electronic databases, including EMBASE, MEDLINE, PubMed, and Cochrane Databases (Cochrane Central Register of Controlled Trials, Cochrane Database of Abstracts of Reviews of Effects), is conducted to gather relevant data.

---

### Operation versus antibiotics — the "appendicitis conundrum" continues: A meta-analysis [^114xSNgF]. The Journal of Trauma and Acute Care Surgery (2017). Low credibility.

Acute appendicitis continues to constitute a diagnostic and therapeutic challenge. The aim of this study was to synthesize evidence from randomized controlled trials (RCTs) comparing nonoperative versus surgical management of uncomplicated acute appendicitis in adult patients.

- **Methods**: A systematic literature search of the PubMed, Cochrane, and Scopus databases was performed with respect to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) statement (end-of-search date: January 29, 2017). Data on the study design, interventions, participants, and outcomes were extracted by two independent reviewers. The random-effects model (DerSimonian-Laird) was used to calculate pooled effect estimates when substantial heterogeneity was encountered; otherwise, the fixed-effects (Mantel-Haenszel) model was implemented. Quality assessment of included RCTs was performed using the modified Jadad scale.

- **Results**: Five RCTs were included in this review. Overall, 1,430 adult patients with uncomplicated acute appendicitis underwent either nonoperative (n = 727) or operative management (n = 703). Treatment efficacy at 1-year follow-up was significantly lower (63.8%) for antibiotics compared with the surgery group (93%) (risk ratio [RR], 0.68; 95% confidence interval, 0.60–0.77; p < 0.001). Overall complications were significantly higher in the surgery group (166/703 [23.6%]) compared with the antibiotics group (56/727 [7.7%]) (RR, 0.32; 95% CI, 0.24–0.43; p < 0.001). No difference was found between the two treatment modalities in terms of perforation.

---

### Journavx [^117VZd1q]. U.S. Food and Drug Administration (2025). High credibility.

The median time to meaningful pain relief, defined as a ≥ 2-point reduction in NPRS, was 119 minutes for patients in the JOURNAVX group and 480 minutes for those in the placebo group. The median time to onset of perceptible pain relief, defined as a ≥ 1-point reduction in NPRS, for patients in the JOURNAVX group was 34 minutes.

---

### Ipratropium bromide [^113VotdM]. U.S. Food and Drug Administration (2010). Low credibility.

Warnings indicate that the use of ipratropium bromide inhalation solution as a single agent for the relief of bronchospasm in acute COPD exacerbation has not been adequately studied. In these situations, drugs with a faster onset of action may be preferable as initial therapy. The combination of ipratropium bromide and beta agonists has not been proven to be more effective than either drug alone in reversing the bronchospasm associated with acute COPD exacerbation.

Immediate hypersensitivity reactions may occur following the administration of ipratropium bromide, as shown by rare cases of urticaria, angioedema, rash, bronchospasm, and oropharyngeal edema.

---

### The NOTA study (non operative treatment for acute appendicitis): Prospective study on the efficacy and safety of antibiotics (amoxicillin and clavulanic acid) for treating patients with right lower quadrant abdominal pain and long-term follow-up of conservatively treated suspected appendicitis [^114zmrSc]. Annals of Surgery (2014). Low credibility.

The study aims to assess the safety and efficacy of antibiotic treatment for suspected acute uncomplicated appendicitis and to monitor the long-term follow-up of non-operated patients.

Right lower quadrant abdominal pain is a common cause of emergency department admission. The natural history of acute appendicitis nonoperatively treated with antibiotics remains unclear. In 2010, a total of 159 patients with a mean Appendicitis Inflammatory Response (AIR) score of 4.9 and a mean Alvarado score of 5.2 were enrolled. They underwent nonoperative management (NOM) with amoxicillin/clavulanate, and the follow-up period was two years.

In terms of results, the short-term (7 days) NOM failure rate was 11.9%, with all patients experiencing initial failure operated on within 7 days. At 15 days, no recurrences were recorded; however, after 2 years, the overall recurrence rate was 13.8% (22 out of 159 patients), with 14 of these 22 patients successfully treated with a further cycle of amoxicillin/clavulanate.

No major side effects occurred. Abdominal pain was assessed using the Numeric Rating Scale (NRS) and the visual analog scale; the median NRS score was 3 at 5 days and 2 after 7 days. The mean length of stay for nonoperatively managed patients was 0.4 days, and the mean sick leave period was 5.8 days. Long-term efficacy of NOM treatment was 83%, with 118 patients recurrence-free and 14 patients with recurrences managed nonoperatively. None of the individual factors forming the Alvarado or AIR scores were independent predictors of NOM failure or long-term recurrence, while the Alvarado and AIR scores were the only independent predictive factors noted.

---

### Clinical indications associated with new opioid use for pain management in the United Kingdom: Using national primary care data [^113FchrQ]. Pain (2025). High credibility.

The opioid crisis in North America, recognized as a public health emergency, has drawn attention to similar concerns in many Western countries. In the United Kingdom, opioid prescriptions have more than doubled over the past two decades, in parallel with a 48.9% increase in opioid-related hospitalizations from 2008 to 2018. In 2021, opioids were involved in nearly half of all UK drug poisoning deaths (45.7%, 2219 fatalities). High levels of opioid prescribing have also raised concerns among policymakers and regulators, including national reviews by Public Health England as well as the Medicines and Healthcare Regulatory Agency.

Opioids have long been prescribed to relieve acute pain. However, for managing chronic pain, the National Institute for Health and Care Excellence, along with the Royal College of Anaesthetists, advise against the initiation of opioids. They advocate for alternatives such as nonpharmacological interventions and non-opioid drugs. Despite growing awareness among healthcare professionals and the general public about the risks associated with their use, opioids are still being prescribed for chronic non-cancer pain due to a diverse set of challenges: limited therapeutic options, biased beliefs about efficacy, and the preferences of both patients and physicians. Previous research from North America suggests that opioids remain a common prescription for several acute and chronic pain conditions, some of which may be more benign, including back pain, surgical recovery, dental, and gynecological pain.

---

### Acute appendicitis: Efficient diagnosis and management [^111h7jEq]. American Family Physician (2018). High credibility.

Regarding the medical management of acute appendicitis, specifically with respect to nonoperative management, the AAFP 2018 guidelines recommend considering nonoperative management with IV antibiotics as a first-line therapy in pediatric and adult patients with uncomplicated acute appendicitis.

---

### SPL drug information for ipratropium bromide [^116ZnNmm]. U.S. Food and Drug Administration. High credibility.

Regarding the use of ipratropium bromide IN (also known as Atrovent, Atrovent HFA) in patients with eGFR 0–90 mL/min/1.73 m²: use with caution.

---

### Ipratropium bromide [^111rzSeR]. U.S. Food and Drug Administration (2023). High credibility.

**Contraindications**: Ipratropium bromide is contraindicated in known or suspected cases of hypersensitivity to ipratropium bromide or to atropine and its derivatives.

---

### SPL drug information for ipratropium bromide [^111CAxdu]. U.S. Food and Drug Administration. High credibility.

Regarding the use of ipratropium bromide INH (also known as Atrovent, Atrovent HFA) in patients with chronic liver disease of any severity: No guidance is available.

---

### Effectiveness of standardized pain management protocols for acute abdominal pain in emergency departments: A systematic review and meta-analysis [^112yFcM7]. The Journal of Emergency Medicine (2025). Low credibility.

Acute abdominal pain constitutes a substantial proportion of emergency department (ED) presentations; yet, pain management remains suboptimal due to historical concerns about masking diagnoses. This systematic review comprehensively evaluates standardized pain management protocols across diverse abdominal pathologies.

- **Objectives**: To assess the effectiveness of standardized pain management protocols compared to usual care in reducing time to analgesia and improving pain relief outcomes for adults presenting to EDs with acute abdominal pain of visceral, biliary, renal, or pelvic origin.

- **Methods**: We systematically searched PubMed/MEDLINE, Cochrane Library, and Web of Science from January 1, 2000, to January 31, 2025. Eligible studies included adults (≥ 18 years) with acute abdominal pain in ED settings, comparing standardized protocols (nurse-initiated, clinical pathways, patient-controlled analgesia, multimodal approaches) to usual care. The primary outcome was time to first analgesia. Secondary outcomes encompassed pain reduction, patient satisfaction, guideline adherence, and diagnostic accuracy. Risk of bias was assessed using Cochrane ROB-2 for randomized controlled trials and the Newcastle-Ottawa Scale for observational studies. Random-effects meta-analyses were conducted with comprehensive sensitivity analyses.

- **Results**: From 621 identified records, 47 studies (n = 8347 patients) met inclusion criteria. Time to analgesia meta-analysis (15 studies, n = 3241) demonstrated substantial reduction with standardized protocols: pooled effect size d = 0.54 (95% confidence interval).

---

### Ipratropium bromide [^1124gcUv]. U.S. Food and Drug Administration (2010). Low credibility.

**Dosage and administration**: The usual dosage of ipratropium bromide inhalation solution is 500 mcg (1 unit-dose vial) administered three to four times a day by oral nebulization, with doses 6 to 8 hours apart. Ipratropium bromide inhalation solution unit-dose vials contain 500 mcg ipratropium bromide anhydrous in 2.5 mL normal saline. Ipratropium bromide inhalation solution can be mixed in the nebulizer with albuterol or metaproterenol if used within one hour. However, drug stability and safety of ipratropium bromide inhalation solution when mixed with other drugs in a nebulizer have not been established.

---

### Laparoscopy for the management of acute lower abdominal pain in women of childbearing age [^112R62Sh]. The Cochrane Database of Systematic Reviews (2011). High credibility.

Acute lower abdominal pain is common, and making a diagnosis is particularly challenging in premenopausal women as ovulation and menstruation symptoms overlap with symptoms of appendicitis and pelvic infection. A management strategy involving early laparoscopy could potentially provide a more accurate diagnosis, earlier treatment, and reduced risk of complications.

- **Objectives**: To evaluate the effectiveness and harms of laparoscopy for the management of acute lower abdominal pain in women of childbearing age.

- **Search strategy**: The Menstrual Disorders and Subfertility Group (MDSG) Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library), MEDLINE, EMBASE, PsycINFO, LILACS, and CINHAL were searched up to April 2010.

- **Selection criteria**: Randomised controlled trials (RCTs) that included women of childbearing age who presented with acute lower abdominal pain, nonspecific lower abdominal pain, or suspected appendicitis were included.

- **Data collection and analysis**: Data from studies that met the inclusion criteria were independently extracted by two authors, and the risk of bias was assessed.

- **Main results**: Laparoscopy was compared with open appendicectomy in eight RCTs. Laparoscopy was associated with an increased rate of specific diagnoses (7 RCTs, 561 participants; OR 4.10, 95% CI 2.50 to 6.71; I² 18%), but there was no evidence of a reduced rate of any adverse event (8 RCTs, 623 participants; OR 0.46, 95% CI 0.19 to 1.10; I² 0%). Laparoscopic diagnosis versus a 'wait and see' strategy was investigated in four RCTs.

---

### CDC clinical practice guideline for prescribing opioids for pain - United States, 2022 [^111tf6pq]. MMWR. Recommendations and Reports (2022). High credibility.

Regarding the medical management of opioids for pain, specifically concerning the choice of agent and dosage, CDC 2022 guidelines recommend assessing benefits and risks carefully. Exercise care when changing the opioid dosage in patients already receiving opioid therapy. Optimize nonopioid therapies while continuing opioid therapy if the benefits outweigh the risks of continued opioid therapy. Optimize other therapies and gradually taper to lower dosages or, if warranted based on the individual circumstances of the patient, appropriately taper and discontinue opioids if the benefits do not outweigh the risks of continued opioid therapy.

---

### Antispasmodics for chronic abdominal pain: Analysis of North American treatment options [^115rNTn1]. The American Journal of Gastroenterology (2021). Low credibility.

- **Results**: The PubMed and Embase database searches identified 492 publications (Figure 2). Eleven additional references were identified from reference lists in relevant review articles and the Cochrane Central Register for Controlled Trials. A total of 26 studies, including 23 IBS and 1 FD, were included. In addition, 2 studies of abdominal pain with cramping (APC) met criteria for inclusion. No studies evaluating antispasmodics in patients with CAPS were identified.

- **Figure 1**: Chemical structure for antispasmodic agents available in North America. (a) alverine, (b) dicyclomine, (c) hyoscine, (d) hyoscyamine, (e) mebeverine, (f) otilonium, (g) pinaverium, (h) trimebutine. Chemical structures reprinted from PubChem.

---

### Salbutamol for analgesia in renal colic: A prospective, randomised, placebo-controlled phase II trial [^1128vMha]. Emergency Medicine Journal (2025). High credibility.

Renal colic is the pain experienced when a renal calculus causes partial or complete obstruction of part of the renal outflow tract. This pain arises from ureteric spasm, increased peristalsis, increased pressure in the renal pelvis, and prostaglandin release with inflammation. The lifetime incidence is approximately 12% in men and 6% in women, with recurrence rates approaching 50%.

Salbutamol is a beta-adrenoreceptor agonist used for multiple indications, with several routes of administration. It has been hypothesized that beta-adrenoreceptor agonists may reduce the pain of renal colic by promoting ureteral relaxation, reducing ureteral contraction frequency, and lowering renal pelvic pressure. Approximately 60% of an intravenous dose of salbutamol is excreted in the urine; therefore, there is potential for both systemic and local action.

The standard analgesic regimens for renal colic are often ineffective and associated with significant side effects. In some studies, fewer than half the participants achieve complete pain relief, many require rescue analgesia within 4 hours, and drowsiness, nausea, and vomiting are frequently reported.

Salbutamol has several potential benefits when compared with existing analgesics. Its onset is faster, it can be administered parenterally (avoiding the problems of gastroparesis, nausea, and vomiting that are frequently associated with renal colic), and its side effects are generally minor and well tolerated. Patients with renal colic may be able to self-medicate with an inhaler, avoiding the need for hospital attendance.

---

### Ipratropium bromide [^113g2WJn]. U.S. Food and Drug Administration (2022). High credibility.

If the nasal tip becomes clogged, remove the clear plastic dust cap and safety clip. Hold the nasal tip under running, warm tap water for about a minute. Dry the nasal tip, reprime the nasal spray pump, and replace the plastic dust cap and safety clip.

- **Caution**: Ipratropium bromide nasal solution 0.06% is intended to relieve rhinorrhea (runny nose) with regular use. It is important that you use ipratropium bromide nasal solution 0.06% as prescribed by your physician. For most patients, improvement in runny nose is usually apparent following the first dose. Do not use ipratropium bromide nasal solution 0.06% for longer than four days for a cold or three weeks for seasonal allergic rhinitis unless instructed by your physician.

Do not spray ipratropium bromide nasal solution 0.06% in your eyes. Should this occur, immediately flush your eye with cool tap water for several minutes. If you accidentally spray ipratropium bromide nasal solution 0.06% in your eyes, you may experience temporary blurring of vision, visual halos, or colored images, along with red eyes from conjunctival and corneal congestion. This may result in the development or worsening of narrow-angle glaucoma, pupil dilation, acute eye pain/discomfort, and increased sensitivity to light, which may last a few hours. Should eye pain or blurred vision occur, contact your doctor promptly.

---

### Racial disparities in pain management of children with appendicitis in emergency departments [^112bHsoE]. JAMA Pediatrics (2015). Low credibility.

Racial disparities in the use of analgesia in emergency departments have been previously documented. Further work to understand the causes of these disparities must be undertaken, which can then help inform the development of interventions to reduce and eradicate racial disparities in healthcare provision.

- **Objective**: To evaluate racial differences in analgesia administration, particularly opioid administration, among children diagnosed with appendicitis.

- **Design, setting, and participants**: This study employed a repeated cross-sectional design, involving patients aged 21 years or younger who were evaluated in the emergency department with an International Classification of Diseases, Ninth Revision, diagnosis of appendicitis. The data were sourced from the National Hospital Ambulatory Medical Care Survey from 2003 to 2010. The frequency of both opioid and nonopioid analgesia administration was calculated using complex survey weighting. Multivariable logistic regression was used to examine racial differences in overall administration of analgesia, specifically opioid analgesia, adjusting for important demographic and visit covariates including ethnicity and pain score.

- **Main outcomes and measures**: The primary outcome was the receipt of analgesia administration (any and opioid) by race.

- **Results**: An estimated 0.94 million children (95% CI, 0.78–1.10) were diagnosed with appendicitis. Of those, 56.8% (95% CI, 49.8%-63.9%) received analgesia of any type, and 41.3% (95% CI, 33.7%-48.9%) received opioid analgesia (20.7% [95% CI, 5.3%-36.0%] of Black patients vs. 43.1% [95% CI, 34.6%-51.4%] of White patients).

---

### What clinical and laboratory parameters determine significant intra abdominal pathology for patients assessed in hospital with acute abdominal pain [^115CmY7q]. World Journal of Emergency Surgery (2007). Low credibility.

Abdominal pain is a very common presentation to the emergency department. It is vital that the physician has an understanding of, and is familiar with, the presentations of common diseases that cause abdominal pain. Patients with acute abdominal pain are a heterogeneous group that consumes a great deal of a surgical department's resources. To streamline efficiency and provide maximum cost-effectiveness, it would be beneficial to identify clinical and laboratory parameters in patients admitted with acute abdominal pain that would indicate no significant intra-abdominal pathology, thereby encouraging early discharge back to the community.

Women of childbearing age commonly present with right iliac fossa pain; most of them do not have appendicitis. Those without the classical features of appendicitis and no evidence of peritonism on examination can be safely managed by active observation or diagnostic laparoscopy. This study was designed to identify the clinical and laboratory red flags. Recognizing these red flags in the history, physical examination, initial imaging, and laboratory findings helps to determine which patients may have a serious underlying disease process and therefore warrant more expedited evaluation and treatment.

---

### Antispasmodics for chronic abdominal pain: Analysis of North American treatment options [^112WE2uM]. The American Journal of Gastroenterology (2021). Low credibility.

The efficacy and safety of otilonium were examined in four randomized, controlled studies. In three studies, otilonium 40 mg t.i.d. decreased the frequency of abdominal pain compared with placebo during weeks 3–4 and at week 15. Otilonium was associated with mild nausea in one study, whereas no adverse events (AEs) were reported with the placebo. In another study, prostate disturbance and dizziness were reported with otilonium, while a skin rash was noted with the placebo; these AEs led to study withdrawal.

In a dose-ranging study, otilonium at doses of 20, 40, and 80 mg t.i.d. decreased the intensity and frequency of abdominal pain and bloating from baseline to four weeks. However, no differences between otilonium and placebo were observed after treatment. Treatment-related AEs with otilonium were generally comparable to those with placebo.

Few details regarding treatment allocation, blinding, and participant attrition were provided for two of the studies, and thus the risks of bias were mostly unclear. One study was at high risk of bias for selective outcome reporting due to a lack of economic data, which was a prespecified outcome.

---

### Extended emergency care for painful conditions [^114839cj]. Emergency Medicine Clinics of North America (2001). Low credibility.

Painful conditions are a common cause for visits to emergency departments. Appropriate therapy often consists of sedating medications followed by a period of observation, which is beneficial in assessing their effect. The cause of abdominal pain is frequently elusive, requiring prolonged testing and re-examination. Observation is particularly beneficial in assessing this condition, while certain other painful conditions are not suitable for emergency observation because of the need for prolonged treatment.

---

### SPL drug information for ipratropium bromide [^113U5TiH]. U.S. Food and Drug Administration. High credibility.

Unknown frequency adverse reactions associated with the use of ipratropium bromide IN (also known as Atrovent, Atrovent HFA) include:

- **Allergic reactions**: anaphylaxis, angioedema, facial edema, urticaria
- **Cardiovascular effects**: atrial fibrillation, supraventricular tachycardia, tachycardia
- **Ocular effects**: blurred vision, conjunctival injection, corneal edema, eye irritation, eye pain, glaucoma, increased intraocular pressure, mydriasis
- **Respiratory effects**: bronchospasm, laryngospasm, throat irritation, wheezing
- **Gastrointestinal effects**: bowel obstruction, constipation, nausea, stomatitis, vomiting
- **Dermatological effects**: pruritus, skin rash
- **Urinary effects**: urinary retention

---

### Journavx [^112nEGY1]. U.S. Food and Drug Administration (2025). High credibility.

**Time to onset of pain relief**: The median time to meaningful pain relief, defined as a ≥ 2-point reduction in the Numerical Pain Rating Scale (NPRS), was 240 minutes for patients in the JOURNAVX group and 480 minutes in the placebo group. The median time to onset of perceptible pain relief, defined as a ≥ 1-point reduction in NPRS, for patients in the JOURNAVX group was 60 minutes.

---

### Guideline for opioid therapy and chronic noncancer pain [^111qtvfi]. CMAJ (2017). High credibility.

Regarding the medical management of opioids for pain, specifically with respect to the choice of agent and dosage, the CMAJ 2017 guidelines recommend considering switching to another opioid in patients with chronic, persistent non-cancer pain who are currently on opioid therapy and experiencing problematic adverse effects.

---

### Conzip [^1137dVBS]. U.S. Food and Drug Administration (2023). High credibility.

- **Indications and usage**: Conzip is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic, for which alternative treatment options are inadequate.

Conzip is an opioid agonist indicated for the management of severe and persistent pain that necessitates extended treatment with a daily opioid analgesic, where alternative treatments are inadequate.

- **Limitations of use**: Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration, and due to the greater risks of overdose and death with extended-release/long-acting opioid formulations, reserve Conzip for use in patients for whom alternative treatment options (e.g. non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or otherwise inadequate to manage pain. Conzip is not indicated as an as-needed (prn) analgesic.

---

### Diagnosis and management of acute appendicitis. EAES consensus development conference 2015 [^114FSEXN]. Surgical Endoscopy (2016). Low credibility.

To reduce surgical trauma further, new treatment strategies have been introduced, such as single-incision laparoscopic surgery (SILS), first reported by Pelosi et al. Since then, numerous studies, including randomized controlled trials (RCTs) and systematic reviews (SR), have been published on the potential advantages and disadvantages of the SILS technique. It can be concluded that SILS is associated with comparable postoperative morbidity rates compared to conventional laparoscopic appendectomy (LA).

The disadvantages of SILS are its increased technical difficulty, reflected in higher technical failure rates, longer operating times, and increased conversion rates. Main advantages would be less postoperative pain and better cosmetic outcomes, although inconsistent results have been reported. At present, evidence is lacking that SILS is superior to conventional LA; however, SILS is a safe and feasible alternative.

Recently, initial non-operative management of appendicitis has been investigated in the adult population. Five RCTs reported an effectiveness of 41–85% at 1-year follow-up. Meta-analyses of these studies have revealed that non-operative treatment of acute appendicitis is less effective but could avoid surgery in 60–85% of patients. Opponents of this strategy raise concerns such as the risk of missing an underlying malignancy and the progression of uncomplicated into complicated appendicitis. Due to the possible avoidance of surgery with an initial non-operative treatment strategy, morbidity was diminished. However, both RCTs and meta-analyses showed significant heterogeneity of methodological quality.

---

### Diagnosis and management of acute appendicitis in adults: A review [^113sunE7]. JAMA (2021). High credibility.

Acute appendicitis is the most common abdominal surgical emergency in the world, with an annual incidence of 96.5 to 100 cases per 100,000 adults.

- **Observations**: The clinical diagnosis of acute appendicitis is based on history and physical examination, laboratory evaluation, and imaging. Classic symptoms of appendicitis include vague periumbilical pain, anorexia, nausea, intermittent vomiting, migration of pain to the right lower quadrant, and low-grade fever. The diagnosis of acute appendicitis is made in approximately 90% of patients presenting with these symptoms. Laparoscopic appendectomy remains the most common treatment. However, increasing evidence suggests that broad-spectrum antibiotics, such as piperacillin-tazobactam monotherapy or combination therapy with either cephalosporins or fluoroquinolones with metronidazole, successfully treat uncomplicated acute appendicitis in approximately 70% of patients. Specific imaging findings on computed tomography (CT), such as appendiceal dilatation (appendiceal diameter ≥ 7 mm) or presence of appendicoliths, defined as the conglomeration of feces in the appendiceal lumen, identify patients for whom an antibiotics-first management strategy is more likely to fail. CT findings of appendicolith, mass effect, and a dilated appendix greater than 13 mm are associated with a higher risk of treatment failure (≈40%) of an antibiotics-first approach. Therefore, surgical management should be recommended for patients with CT findings of appendicolith, mass effect, or a dilated appendix who are fit for surgery.

---

### Methods of conservative antibiotic treatment of acute uncomplicated appendicitis: A systematic review [^115EsRaw]. The Journal of Trauma and Acute Care Surgery (2019). Low credibility.

The most common total intravenous and oral antibiotic duration was 7 to 10 days. Four trials (12%) used only a 4-day duration. The Study to Optimize Peritoneal Infection Therapy trial demonstrated that antibiotic treatment for a median of 4 days (i.e. 2 days after symptom resolution) resulted in similar outcomes as treatment for a median of 8 days among patients with intra-abdominal infection. As opposed to conservative management of appendicitis, all patients in the Study to Optimize Peritoneal Infection Therapy trial had source control. However, among studies of nonoperative treatment of appendicitis, lower initial antibiotic response rates did not appear to be associated with shorter treatment duration, suggesting a shorter antibiotic course may be possible.

Guidelines do not recommend broad-spectrum regimens with activity against *Pseudomonas aeruginosa* and fluoroquinolone-resistant and extended-spectrum β-lactamase–producing bacteria for patients with mild-to-moderate community-acquired infections unless antimicrobial resistance risk factors exist, such as recent antimicrobial exposure, past infection with a resistant strain, or high prevalence of resistance in the patient's community or recent areas of travel. Several trials used broad-spectrum regimens such as piperacillin-tazobactam or meropenem, which are discouraged by guidelines to promote antibiotic stewardship.

A major limitation of most past trials is the absence of any specific pain control protocol or description of the extent to which pain control was achieved. Persistent or worsening symptoms were considered…

---

### Global strategy for asthma management and prevention [^117YNbRp]. GINA (2025). High credibility.

Regarding medical management for asthma, specifically in the context of managing exacerbations in an emergency department setting, the GINA 2025 guidelines recommend considering the administration of ipratropium in addition to short-acting β-agonists. This combination is suggested for managing moderate-to-severe exacerbations to reduce hospitalizations in adult, adolescent, and pediatric patients, as well as to improve peak expiratory flow and FEV₁ in adolescent and adult patients.

---

### SPL drug information for ipratropium bromide [^113y7412]. U.S. Food and Drug Administration. High credibility.

Unknown frequency adverse reactions associated with the use of ipratropium bromide inhalation (also known as Atrovent, Atrovent HFA) include anaphylaxis, angioedema, diarrhea, increased intraocular pressure, laryngospasm, mydriasis, skin rash, tachycardia, urinary retention, urticaria, and vomiting.

---

### Fentanyl transdermal [^115CTqf5]. U.S. Food and Drug Administration (2024). High credibility.

Fentanyl transdermal system is contraindicated in several instances:

- **Opioid non-tolerant patients**: The system should not be used in patients who are not opioid-tolerant.

- **Pain management**: It is not suitable for management of acute or intermittent pain, or in patients who require opioid analgesia for short periods. It is also contraindicated for postoperative pain management, including after out-patient or day surgeries such as tonsillectomies, and for the management of mild pain.

- **Respiratory conditions**: The system is contraindicated in patients with significant respiratory depression and in those with acute or severe bronchial asthma if in an unmonitored setting or without resuscitative equipment [see Warnings and Precautions (5.12)].

- **Gastrointestinal obstruction**: Patients with known or suspected gastrointestinal obstruction, including paralytic ileus, should not use the fentanyl transdermal system [see Warnings and Precautions (5.19)].

- **Hypersensitivity**: It is contraindicated in patients with known hypersensitivity to fentanyl or any components of the transdermal system, including cases of anaphylaxis [see Adverse Reactions (6.2)].

---

### SPL drug information for ipratropium bromide [^115LKZ2X]. U.S. Food and Drug Administration. High credibility.

The dosage of ipratropium bromide inhalation for the treatment of chronic obstructive pulmonary disease in adults is 500 mcg inhaled every 6–8 hours using a nebulized solution.

---

### Postoperative pain management in non-traumatic emergency general surgery: WSES-GAIS-SIAARTI-AAST guidelines [^111fiLz4]. World Journal of Emergency Surgery (2022). High credibility.

Regarding preventative measures for postoperative pain, specifically with respect to preemptive analgesia, AAST/GAIS/SIAARTI/WSES 2022 guidelines recommend considering the administration of preemptive analgesia to reduce postoperative opioid consumption.

---

### Effect on diagnostic efficiency of analgesia for undifferentiated abdominal pain [^112mUce2]. The British Journal of Surgery (2003). Low credibility.

The question of whether it is safe to provide analgesia for patients with undifferentiated acute abdominal pain is marked by longstanding controversy over the possible masking of physical findings. This review aims to assess the pertinent studies.

- **Method**: A Medline search was performed in April 2002, using the terms 'analgesia', 'abdominal pain', 'acute abdomen', and 'morphine'. Additional articles were identified using the bibliographies of papers found through Medline. All articles reporting clinical trials of analgesia and its effects on diagnosis or physical examination were reviewed.

- **Results**: A total of eight trials (one reported only as an abstract) were identified. Because of significant disparity in trial design, no formal analysis, such as a meta-analysis, was performed. However, a detailed review of the trials revealed a striking consistency in results. In no study was there an association between analgesia and diagnostic impairment or dangerous masking of the findings of physical examination.

- **Conclusion**: The literature addressing early pain relief for abdominal pain is characterized by weaknesses, but there is a common theme suggesting that analgesia is safe. Pending further research, which should address some of the shortcomings of extant studies, a practice of judicious provision of analgesia appears safe, reasonable, and in the best interests of patients in pain.

---

### Acute appendicitis in the elderly: Risk factors for perforation [^116jAmF9]. World Journal of Emergency Surgery (2014). Low credibility.

Other factors that may influence patient outcomes were not specifically addressed in this analysis, but are relevant to medical decision-making in cases of appendicitis.

Reports in the literature have described the advantages of laparoscopic surgery over the open technique in terms of decreasing postoperative pain, recovery time, wound complications, and hospital stay. However, other studies found that referring an elderly patient with complicated appendicitis to laparoscopic surgery may increase the operative time, conversion rate, and length of hospital stay. In a recent study published in 2013, Wray CJ et al. concluded that the question of whether appendectomy should be performed via an open or laparoscopic technique has been inherently difficult to answer because both approaches offer similar advantages: a small incision, low incidence of complications, short hospital stay, and rapid return to normal activity. At our hospitals, the laparoscopic approach has been adopted for treating appendicitis in younger age groups but not yet for elderly patients.

Despite appendectomy being regarded as the standard treatment for appendicitis for over 100 years, several reports have appeared in the literature in recent years describing nonoperative management of acute, uncomplicated appendicitis. This conservative treatment, which consists of nil by mouth, intravenous fluids, and broad-spectrum antibiotics, has proved effective with less pain but has a high recurrence rate — a risk that should be considered.

---

### Approaching acute pain in emergency settings; European Society for Emergency Medicine (EUSEM) guidelines-part 2: management and recommendations [^115GJbYa]. Internal and Emergency Medicine (2020). High credibility.

In the medical management of acute pain, particularly regarding non-opioid analgesics, the EUSEM 2020 guidelines highlight that non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, diclofenac, ketoprofen, and naproxen are widely used in both pre-hospital and emergency department settings for mild-to-moderate pain, especially when there is an inflammatory component. These NSAIDs are most commonly administered orally, intravenously, or topically. They are the preferred analgesic option for renal colic, demonstrating equivalence to opioid or opioid-acetaminophen combined analgesia at 30 minutes and providing effective analgesia in cases of fracture.

---

### Evidence-based, cost-effective management of acute appendicitis: An algorithm of the Journal of Trauma and Acute Care Surgery emergency general surgery algorithms work group [^111mMYUn]. The Journal of Trauma and Acute Care Surgery (2025). High credibility.

Evaluation of the patient with abdominal pain begins with a thorough history and physical examination (Fig. 1). Patients typically present with 12 to 24 hours of mid-abdominal pain, which may migrate to the right lower quadrant. In the early course of appendicitis, the physical examination may reveal nonlocalizing, mid-abdominal pain without peritoneal irritation.

Additional symptoms may include loss of appetite, abdominal distention, nausea, vomiting, malaise, obstipation, fever, and chills. Patients may also have certain physical signs associated with appendicitis.

- **Psoas sign**: This is an irritation of the iliopsoas muscle in the abdomen, a classic finding of acute appendicitis, which can be elicited by performing passive extension of the right hip with the patient lying on their left side.

- **Rovsing's sign**: This sign can also be seen in acute appendicitis and is observed when deep palpation of the left lower quadrant elicits pain in the right lower quadrant.

Patients presenting later in the course of the disease process may develop peritoneal inflammation with localized guarding and rebound tenderness adjacent to the appendix in the right lower quadrant.

Standard laboratory tests should include a complete blood count, urine analysis, and routine chemistry if the patient requires further imaging or operative management. It is important to note that the white blood cell count may not be elevated in early acute appendicitis. A urine analysis would be conducted as needed.

---

### AtroventHFA [^1113q3GE]. U.S. Food and Drug Administration (2025). High credibility.

**Overdosage**: Acute overdose by inhalation is unlikely, as ipratropium bromide is not well absorbed systemically after inhalation or oral administration.

---

### Ipratropium bromide [^112wRp9V]. U.S. Food and Drug Administration (2010). Low credibility.

Adverse reaction information concerning Ipratropium Bromide Inhalation Solutions is derived from 12-week active-controlled clinical trials. Additional information is derived from foreign postmarketing experience and the published literature. All adverse events, regardless of drug relationship, reported by three percent or more of patients in the 12-week controlled clinical trials appear in the table below.

Additional adverse reactions reported in less than three percent of the patients treated with ipratropium bromide include tachycardia, palpitations, eye pain, urinary retention, urinary tract infection, and urticaria. Cases of precipitation or worsening of narrow-angle glaucoma and acute eye pain have been reported.

Lower respiratory adverse reactions (bronchitis, dyspnea, and bronchospasm) were the most common events leading to discontinuation of ipratropium bromide therapy in the 12-week trials. Headache, mouth dryness, and aggravation of COPD symptoms are more common when the total daily dose of ipratropium bromide equals or exceeds 2,000 mcg.

Allergic-type reactions, such as skin rash, angioedema of the tongue, lips, and face, urticaria, laryngospasm, and anaphylactic reactions, have been reported. Many of the patients had a history of allergies to other drugs and/or foods.

---

### Diagnosis and management of acute appendicitis [^115bziyH]. Surgical Endoscopy (2016). Low credibility.

Use of prophylactic anti-emetics diminishes the incidence of post-operative nausea and vomiting. The decision to advance the diet should be based on the patient's ability to tolerate oral intake. There is no evidence suggesting that a liberal diet causes complications during the post-operative period.

Post-operative pain management should adhere to local protocols for pain management following abdominal surgery. Post-operative analgesia using patient-controlled analgesia (PCA) provides effective and safe pain relief for both children and adults, and is less time-consuming. Recent studies have shown positive results regarding pre-emptive incision site infiltration with local anaesthetic, which decreases total opioid consumption and lowers pain scores experienced by patients in the first 24 hours after surgery.

---

### Diagnosis and management of acute appendicitis [^117V5BMw]. Surgical Endoscopy (2016). High credibility.

Regarding specific circumstances for acute appendicitis, more specifically with respect to patients with immunosuppression, the EAES 2016 guidelines recommend considering treating immunosuppressed patients with appendicitis following the same approach as outlined for immunocompetent patients.

---

### SPL drug information for ipratropium bromide / albuterol sulfate [^114SjhQm]. U.S. Food and Drug Administration. High credibility.

Common adverse reactions (1–10%) associated with the use of ipratropium / albuterol INH, also known as Combivent Respimat, include:

- **Musculoskeletal and joint related**: arthralgia, muscle spasms, myalgia

- **General symptoms**: asthenia, fatigue, flu-like symptoms

- **Respiratory issues**: bronchitis, bronchospasm, cough, dyspnea, nasopharyngitis, sinusitis, sputum production, throat dryness, upper respiratory tract infections, wheezing

- **Gastrointestinal issues**: change in taste, constipation, diarrhea, dry mouth, dyspepsia, nausea, vomiting

- **Cardiovascular issues**: chest discomfort, hypertension, palpitations, tachycardia

- **Neurological and psychological issues**: dizziness, headache, insomnia, nervousness, tremor

- **Urinary and renal issues**: dysuria, urinary tract infections

- **Dermatological and other issues**: eye pain, pruritus, skin rash

- **Other symptoms**: decreased serum potassium

---

### Ipratropium bromide [^117EDKaB]. U.S. Food and Drug Administration (2022). High credibility.

In cases of acute overdosage via intranasal administration, significant systemic absorption of ipratropium bromide is improbable. This is because ipratropium bromide is not efficiently absorbed systemically after intranasal or oral administration. In a study involving 10 male volunteers, ingestion of a 20 mg oral dose (equivalent to consuming more than two bottles of ipratropium bromide 0.06%) resulted in no observable changes in heart rate or blood pressure. However, following a 2 mg intravenous infusion over 15 minutes administered to the same group, plasma ipratropium concentrations ranged from 22 to 45 ng/mL — levels exceeding 100 times those recorded after intranasal administration. During this intravenous infusion, a mean heart rate increase of 50 bpm was recorded, accompanied by less than a 20 mmHg change in systolic or diastolic blood pressure at the peak of ipratropium levels.

---

### Methods of conservative antibiotic treatment of acute uncomplicated appendicitis: A systematic review [^114gWLDx]. The Journal of Trauma and Acute Care Surgery (2019). Low credibility.

This systematic review identifies patient populations most studied, common selection criteria, and care methods. It provides critical analysis in the context of applicable clinical guidelines and related research and highlights areas of uncertainty so that patients can be best informed and managed should they consider this approach. Researchers can better target unanswered questions about this care. Future studies that address biases associated with enrollment and response evaluation, use best-practice pain control and antibiotic selection, better define cancer risk, and explore longer time thresholds for response, minimized diet restriction and hospital stays, and antibiotic retreatment will further our understanding of the potential effectiveness of conservative management.

---

### Effects of pain severity and CT imaging on analgesia prescription in acute appendicitis [^116wNhto]. The American Journal of Emergency Medicine (2016). Low credibility.

Previously, analgesics were avoided in suspected appendicitis to prevent masking the diagnosis. This study aimed to determine the use of analgesia in patients with appendicitis to assess recent trends over time and explore predictors of analgesia use.

- **Methods**: A retrospective review of the National Hospital Ambulatory Medical Care Survey from 2006 to 2010 was conducted. This analysis included emergency department (ED) patients with acute appendicitis (ICD-9-CM 540.xx). The association between demographic and clinical information and the ED visit prescription of analgesics or opioids was determined using univariate (χ²) and multivariate (logistic regression) analyses.

- **Results**: There were an estimated 763,000 ED patient visits for acute appendicitis from 2006 to 2010. The mean age was 32 years, with 74% of patients under age 19, and 69% were male. Sixty-four percent of patients received any analgesia in the ED and 58% received an opioid; use of analgesics did not change over time. Among all patients, 68% underwent computed tomographic (CT) imaging. There was a positive trend in analgesic use with increasing pain (27% for no pain to 71% for severe pain, P = 0.08); a similar trend was observed for opioids, though it was not significant (P = 0.12). Analgesic use was lower for elderly patients (age > 65) with an odds ratio [OR] of 0.09 and a 95% confidence interval [CI] of 0.01–0.56, and for those with private insurance (OR 0.14, 95% CI 0.05–0.43). However, analgesic use was higher for patients with CT scans (OR 3.73, 95% CI 1.61–8.66). Pain severity was not associated with the administration of analgesics after controlling for other factors.

- **Conclusions**: The use of analgesia and opioid analgesia has remained stable over the study period.

---

### Sprix [^113upqmG]. U.S. Food and Drug Administration (2024). High credibility.

The effect of Sprix on acute pain was evaluated in two multi-center, randomized, double-blind, placebo-controlled studies.

- **Postoperative pain**: In a study of adults who had undergone elective abdominal or orthopedic surgery, 300 patients were randomized and treated with Sprix or placebo administered every 8 hours and morphine administered via patient-controlled analgesia on an as-needed basis. Efficacy was demonstrated as a statistically significant greater reduction in the summed pain intensity difference over 48 hours in patients who received Sprix compared to those receiving placebo. The clinical relevance of this is reflected in the finding that patients treated with Sprix required 36% less morphine over 48 hours than patients treated with placebo.

In another study of adults who had undergone elective abdominal surgery, 321 patients were randomized and treated with Sprix or placebo administered every 6 hours and morphine administered via patient-controlled analgesia on an as-needed basis. Efficacy was demonstrated as a statistically significant greater reduction in the summed pain intensity difference over 48 hours in patients who received Sprix compared to those receiving placebo. The clinical relevance of this is reflected in the finding that patients treated with Sprix required 26% less morphine over 48 hours than patients treated with placebo.

---

### Ipratropium bromide [^111U3S39]. U.S. Food and Drug Administration (2023). High credibility.

- **Patient's instructions for use**: Ipratropium Bromide Inhalation Solution, 0.02%. Read complete instructions carefully before using.

1. Remove vial from the foil pouch.

2. Twist open the top of one unit dose vial and squeeze the contents into the nebulizer reservoir (Figure 1).

3. Connect the nebulizer reservoir to the mouthpiece or face mask (Figure 2).

4. Connect the nebulizer to the compressor.

5. Sit in a comfortable, upright position; place the mouthpiece in your mouth (Figure 3) or put on the face mask and turn on the compressor. If a face mask is used, care should be taken to avoid leakage around the mask as temporary blurring of vision, pupil enlargement, precipitation or worsening of narrow-angle glaucoma, or eye pain may occur if the solution comes into direct contact with the eyes.

6. Breathe as calmly, deeply, and evenly as possible until no more mist is formed in the nebulizer chamber (about 5 to 15 minutes). At this point, the treatment is finished.

7. Clean the nebulizer (see manufacturer's instructions).

- **Note**: Use only as directed by your physician. More frequent administration or higher doses are not recommended. Ipratropium Bromide Inhalation Solution can be mixed in the nebulizer with albuterol or metaproterenol if used within one hour but not with other drugs. Drug stability and safety of Ipratropium Bromide Inhalation Solution when mixed with other drugs in a nebulizer have not been established. Store between 15° and 30°C (59° and 86°F). Protect from light. Store in pouch until time of use.

---

### Ipratropium bromide [^115FDekT]. U.S. Food and Drug Administration (2022). High credibility.

Patients should be advised that temporary blurring of vision, precipitation or worsening of narrow-angle glaucoma, mydriasis, increased intraocular pressure, acute eye pain or discomfort, visual halos, or colored images in association with red eyes from conjunctival and corneal congestion may result if ipratropium bromide comes into direct contact with the eyes. Patients should be instructed to avoid spraying ipratropium bromide in or around their eyes. Patients who experience eye pain, blurred vision, excessive nasal dryness, or episodes of nasal bleeding should be instructed to contact their doctor. To ensure proper dosing, patients should be advised not to alter the size of the nasal spray opening. Patients should be reminded to carefully read and follow the accompanying "Patient's Instructions for Use".

Since dizziness, accommodation disorder, mydriasis, and blurred vision may occur with the use of ipratropium bromide, patients should be cautioned about engaging in activities requiring balance and visual acuity, such as driving a car or operating appliances and machinery.

- **Drug interactions**: No controlled clinical trials were conducted to investigate potential drug-drug interactions. There is potential for an additive interaction with other concomitantly administered medications with anticholinergic properties, including ipratropium bromide for oral inhalation.

- **Carcinogenesis, mutagenesis, impairment of fertility**: Two-year oral carcinogenicity studies in rats and mice have revealed no carcinogenic activity at doses up to 6 mg/kg. This dose corresponds to…

---

### Opioids for acute pancreatitis pain [^115KYUkS]. The Cochrane Database of Systematic Reviews (2013). Low credibility.

Acute pancreatitis is an inflammatory process of the pancreas that may also involve adjacent tissues and/or remote organ systems. Abdominal pain is the main symptom, usually accompanied by nausea, vomiting, and fever. Opioids are commonly used to manage pain in acute pancreatitis, but uncertainties about their clinical effectiveness and safety remain.

- **Objectives**: To assess the effectiveness and safety of opioids for treating acute pancreatitis pain.

- **Search methods**: The search strategy included the Cochrane Upper Gastrointestinal and Pancreatic Diseases Review Group Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (2013, Issue 6), MEDLINE (from 1950 to June 2013), and EMBASE (from 1980 to June 2013). There were no restrictions by language or publication status.

- **Selection criteria**: We considered randomized clinical trials (RCTs) assessing the effectiveness of any opioid drug used for treating acute pancreatitis pain.

- **Data collection and analysis**: Two review authors independently selected studies, assessed risks of bias, and extracted data. We estimated risk ratios (RRs) for dichotomous data and calculated a 95% confidence interval (CI) for each RR. We performed an intention-to-treat (ITT) analysis and undertook meta-analysis for some outcomes.

- **Main results**: We included five RCTs with a total of 227 participants (age range 23 to 76 years; 65% men) with acute pancreatitis pain. The opioids assessed were intravenous and intramuscular buprenorphine, intramuscular pethidine, and intravenous administration.

---

### CDC clinical practice guideline for prescribing opioids for pain - United States, 2022 [^117DWjZi]. MMWR. Recommendations and Reports (2022). High credibility.

Regarding the medical management of opioids for pain, particularly concerning non-opioid therapies, the CDC 2022 guidelines recommend maximizing the use of nonpharmacologic and nonopioid pharmacologic therapies as appropriate for the specific condition before initiating opioid therapy for acute, subacute, or chronic pain. It is important to recognize that nonopioid therapies are at least as effective as opioids for many common types of acute pain. Meanwhile, nonopioid therapies are preferred for subacute and chronic pain.

---

### Exercise-induced bronchoconstriction update-2016 [^112EnWT3]. The Journal of Allergy and Clinical Immunology (2016). High credibility.

Regarding medical management for exercise-induced bronchoconstriction, the AAAAI/ACAAI 2016 guidelines specifically recommend considering the administration of inhaled ipratropium bromide in patients who do not respond to other agents. It is recognized that the ability of inhaled ipratropium bromide to attenuate exercise-induced bronchoconstriction (EIB) is inconsistent.

---

### SPL drug information for ipratropium bromide [^113NDdri]. U.S. Food and Drug Administration. High credibility.

Ipratropium bromide INH, also known as Atrovent or Atrovent HFA, is contraindicated for use in the relief of acute bronchospasm.

---

### Is there an ideal morphine dose for prehospital treatment of severe acute pain? A randomized, double-blind comparison of 2 doses [^114YjNgu]. The American Journal of Emergency Medicine (2008). Low credibility.

The study aimed to determine the best intravenous morphine titration protocol by comparing two protocols for prehospital treatment of patients with severe acute pain.

- **Methods**: Eligible patients with a numerical rating scale (NRS) score of 60/100 or higher were randomly allocated to receive either 0.05 mg/kg morphine followed by 0.025 mg/kg every 5 minutes (group A) or 0.1 mg/kg morphine followed by 0.05 mg/kg every 5 minutes (group B) intravenously. The protocol-defined primary outcome measure was the percentage of patients achieving pain relief (with an NRS score of 30/100 or lower) 30 minutes after the first injection.

- **Results**: A total of 106 consecutive patients were randomized. Thirty minutes after the injection, 66% of patients in group A had an NRS of 30 or lower compared to 76% in group B (P = 0.25). Ten minutes after the injection, 17% of the patients in group A had an NRS score of 30 or lower versus 40% in group B (odds ratio, 3.4; 95% confidence interval, 1.3–8.8; P < .01). Patients in group B were significantly more satisfied with their analgesia. While there were no serious complications in either group, patients in group B experienced almost twice the incidence of adverse effects overall, and in particular, four times the level of emesis, although neither of these findings were statistically significant. Using univariate and multivariate analysis, only an initial NRS score of 100 was an independent predictive factor for failure of analgesia (odds ratio, 0.125; 95% confidence interval, 0.02–0.68; P < .05).

- **Conclusion**: The high-dose morphine regimen appeared to provide greater patient satisfaction and quicker pain relief, despite a higher incidence of adverse effects; however, the significance of the adverse effects was not conclusively established.

---

### SPL drug information for ipratropium bromide / albuterol sulfate [^114qfxNr]. U.S. Food and Drug Administration. High credibility.

Labeled indications for ipratropium/albuterol (also known as Combivent Respimat) include the treatment of chronic obstructive pulmonary disease in adults.

---

### Ipratropium bromide [^111Ais2i]. U.S. Food and Drug Administration (2010). Low credibility.

Ipratropium bromide inhalation solution, administered either alone or with other bronchodilators, especially beta-adrenergics, is indicated as a bronchodilator for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.

---

### Endogenous opioids contribute to the feeling of pain relief in humans [^114D4nVY]. Pain (2021). Low credibility.

The average magnitude of the endogenous opioid blockade effect across participants (ranging from −8.13 to −4.71 points on the VAS) is comparable with observed reductions in placebo and relative relief-induced analgesia after opioid blockade. An exploratory analysis of how much pain relief individuals reported in the placebo session and the magnitude of naltrexone effects on pain relief first revealed a negative association, i.e. the greater the pain relief in the placebo session, the greater the naltrexone reduction of pain relief.

However, the comparison to a randomly generated sample of 10,000 correlation coefficients showed that none of the observed correlations were different from what would be expected by the statistical flaw of a random string of numbers A typically correlating with a random string B-A using inherently correlated samples A and B. The observed high interindividual variability of perceived pain relief, therefore, seems not to be related to how pain relief is modulated by endogenous opioid blockade on an individual level.

Nevertheless, interindividual differences in the endogenous opioid system might contribute to differences across individuals in how they perceive pain relief, similar to what has been described for pain perception and clinical opioid effects. It is also conceivable that the feeling of pain relief involves other neurotransmitter systems than endogenous opioids, which would not be modulated by naltrexone. Besides, individuals may present with inherently different pain relief rating behaviors, as has been reported for pain ratings.

---

### SPL drug information for ipratropium bromide [^115gBa5N]. U.S. Food and Drug Administration. High credibility.

Regarding the use of ipratropium bromide IN (also known as Atrovent, Atrovent HFA) in patients with chronic liver disease of any severity: use with caution.

---

### Development of evidence-based recommendations for procedure-specific pain management: PROSPECT methodology [^114VfyJA]. Anaesthesia (2019). High credibility.

A modified Delphi approach is utilized, incorporating several rounds of individual comments followed by round-table discussions. Each Working Group member provides comments to the sub-group leader via email. These comments are collated for presentation during the face-to-face meeting when one of the sub-group members presents evidence and the reasons for recommendations. This is followed by a discussion among the members, and a consensus is developed, but any disagreements are recorded as a matter of good practice.

The group also develops clinical questions that need to be addressed in the future for each procedure. After the face-to-face meeting, the sub-group prepares a final document, which includes edits based on the discussions during the meeting. The final document with the consensus agreements is circulated to the Working Group for review and approval, with no major changes incorporated during this stage. Finally, the sub-group prepares a manuscript for publication in a peer-reviewed journal, if appropriate. Subsequently, a web copy is prepared with the help of a medical writer. Notably, the PROSPECT website also includes the overall recommendations in several languages.

---

### Ipratropium bromide [^111NKagi]. U.S. Food and Drug Administration (2024). High credibility.

Attention pharmacist: Detach "Patient's Instructions for Use" from the package insert and dispense with the product.

---

### SPL drug information for ipratropium bromide [^113yFPEK]. U.S. Food and Drug Administration. High credibility.

Common adverse reactions (1–10%) associated with the use of ipratropium bromide INH (also known as Atrovent, Atrovent HFA) include:

- **Musculoskeletal and respiratory reactions**: back pain, bronchospasm, chest pain
- **Neurological and general symptoms**: dizziness, headache, flu-like symptoms
- **Gastrointestinal issues**: dry mouth, dyspepsia, nausea
- **Respiratory effects**: cough, dyspnea, pharyngitis, rhinitis, sputum production
- **Infections**: urinary tract infections

---

### Ipratropium bromide [^115EjZVC]. U.S. Food and Drug Administration (2024). High credibility.

Ipratropium bromide nasal solution, 0.06% should be used with caution in patients with narrow-angle glaucoma, prostatic hyperplasia, or bladder neck obstruction, particularly if they are receiving an anticholinergic by another route. It has not been studied in patients with hepatic or renal insufficiency, so it should be used cautiously in those populations.

Patients should be advised that temporary blurring of vision, precipitation or worsening of narrow-angle glaucoma, mydriasis, increased intraocular pressure, acute eye pain or discomfort, visual halos, or colored images in association with red eyes from conjunctival and corneal congestion may result if ipratropium bromide nasal solution, 0.06% comes into direct contact with the eyes. Patients need to avoid spraying ipratropium bromide nasal solution, 0.06% in or around their eyes. If they experience eye pain, blurred vision, excessive nasal dryness, or episodes of nasal bleeding, they should contact their doctor. To ensure proper dosing, patients should be advised not to alter the size of the nasal spray opening and should be reminded to carefully read and follow the accompanying instructions for use.

Since dizziness, accommodation disorder, mydriasis, and blurred vision may occur with the use of ipratropium bromide nasal solution, 0.06%, patients should be cautioned about engaging in activities requiring balance and visual acuity.

---

### Ipratropium bromide [^115iafAh]. U.S. Food and Drug Administration (2023). High credibility.

The usual dosage of ipratropium bromide inhalation solution is 500 mcg (1 unit-dose vial) administered three to four times a day by oral nebulization, with doses 6 to 8 hours apart. Ipratropium bromide inhalation solution unit-dose vials contain 500 mcg ipratropium bromide, USP anhydrous in 2.5 mL normal saline. Ipratropium bromide inhalation solution can be mixed in the nebulizer with albuterol or metaproterenol if used within one hour. The drug stability and safety of ipratropium bromide inhalation solution when mixed with other drugs in a nebulizer have not been established.

---

### Hysingla ER [^113fF4yD]. U.S. Food and Drug Administration (2023). High credibility.

Hysingla ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. It is an opioid agonist suitable for such conditions.

- **Limitations of use**: Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration, and because of the greater risks of overdose and death with extended-release/long-acting opioid formulations [see Warnings and Precautions (5.1)], reserve Hysingla ER for use in patients for whom alternative treatment options (e.g. non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Hysingla ER is not indicated as an as-needed (prn) analgesic.

---

### Ipratropium bromide [^111RjScd]. U.S. Food and Drug Administration (2010). Low credibility.

Ipratropium bromide is contraindicated in known or suspected cases of hypersensitivity to ipratropium bromide, or to atropine and its derivatives.

---

### Nebulized fentanyl vs intravenous morphine for ED patients with acute abdominal pain: A randomized double-blinded, placebo-controlled clinical trial [^1141vve2]. The American Journal of Emergency Medicine (2015). Low credibility.

Patients with acute abdominal pain commonly present to emergency departments. The safe and effective relief of discomfort is a concern for both patients and physicians. Intravenous opioids are the traditional method used to provide pain relief in this setting, but intravenous access is time-consuming and not always achievable. Therefore, alternative methods of pain control may be necessary for the acute management of painful conditions without adding to the overall physical or psychological discomfort.

The purpose of this study was to evaluate the feasibility of nebulized fentanyl (NF) in alleviating acute and undifferentiated abdominal pain. We also sought to compare NF with intravenous morphine (IVM) and assess patient and provider satisfaction with NF. Nebulized fentanyl (2 μg/kg) was compared to IVM (0.1 mg/kg) at 10, 20, 30, and 40 minutes; patient and physician satisfaction was recorded. The NF group experienced more rapid and sustained clinically significant pain relief over the 40-minute study interval. There were no adverse effects noted in the NF group. Both patient and physician satisfaction scores were higher in the NF group. Fentanyl citrate at a dose of 2 μg/kg through a breath-actuated nebulizer appears to be a feasible and safe alternative to IVM (0.1 mg/kg) in the treatment of acute abdominal pain.

---

### Ipratropium bromide [^11692LuP]. U.S. Food and Drug Administration (2023). High credibility.

Use of ipratropium bromide inhalation solution as a single agent for the relief of bronchospasm in acute COPD exacerbation has not been adequately studied. Drugs with a faster onset of action may be preferable as initial therapy in this situation. The combination of ipratropium bromide inhalation solution and beta agonists has not been shown to be more effective than either drug alone in reversing the bronchospasm associated with acute COPD exacerbation.

Immediate hypersensitivity reactions may occur after administration of ipratropium bromide, as demonstrated by rare cases of urticaria, angioedema, rash, bronchospasm, and oropharyngeal edema.

---

### Evidence-based medicine approach to abdominal pain [^1114fmQt]. Emergency Medicine Clinics of North America (2016). Low credibility.

The chief complaint of abdominal pain accounts for 5% to 10% of all presentations in the emergency department. With such broad differentials and diagnostic modalities available, this article focuses on a systematic approach to evaluating abdominal pain, which is essential to providing patients with efficient and accurate care.

---

### Pain solutions in the emergency setting (PASTIES) — patient controlled analgesia versus routine care in emergency department patients with non-traumatic abdominal pain: randomised trial [^115tknzo]. BMJ (2015). High credibility.

Despite the high prevalence of pain in emergency department patients, evidence relating to the use of PCA in this setting is very limited. Previous studies in this area have provided limited evidence of the short-term utility of PCA in emergency patients but have not considered the management of pain over the subsequent hours after hospital admission. We identified no previous studies that combine emergency department care with ongoing ward care to assess the quality of pain relief beyond four hours, and no detailed analysis of the cost-effectiveness of PCA in this setting has been reported.

Most painful conditions leading to ED attendance may be subdivided into abdominal (visceral) and musculoskeletal (somatic) pain. Any effect of PCA, compared with usual care, may differ between visceral and somatic pain. Pain from skeletal injury tends to be well localized and proportionate to the degree of trauma in most patients. In contrast, visceral pain is poorly localized, often does not reflect the severity of pathology, and is associated with referred sensations. Strong autonomic and emotional responses to visceral pain often occur. These differences reflect the differing neurobiology of the two broad types of pain. We therefore considered patients with abdominal pain and patients with pain from musculoskeletal trauma as two separate populations and conceived two separately powered trials.

The aim of the study reported here was to compare morphine delivered by PCA with routine care.

---

### SPL drug information for ipratropium bromide [^115wSB43]. U.S. Food and Drug Administration. High credibility.

Labeled indications for ipratropium bromide (also known as Atrovent, Atrovent HFA) include the treatment of chronic obstructive pulmonary disease in adults and the treatment of bronchospasm in adults with chronic obstructive pulmonary disease.

- **Off-label indications**: Adjunctive treatment for asthma exacerbation in adults (moderate-to-severe).

---

### Lortab [^1135g1so]. U.S. Food and Drug Administration (2016). Low credibility.

Lortab Elixir is indicated for the relief of moderate to moderately severe pain.

---

### Ipratropium bromide for acute asthma exacerbations in the emergency setting: A literature review of the evidence [^111fzTGS]. Pediatric Emergency Care (2009). Low credibility.

Since the 1970s, when inhaled anticholinergic agents were first introduced as adjunct therapies for the immediate treatment of pediatric asthma exacerbations, several trials have shown varying degrees of benefit from their use as bronchodilators in combination with inhaled short-acting beta-adrenergic agonists and systemic corticosteroids. Although other anticholinergics exist, ipratropium bromide (IB) specifically has emerged as the overwhelming choice of pulmonologists and emergency physicians because of its limited systemic absorption from the lungs when given as an inhaled preparation.

However, although the varying trials, predominantly in the emergency department setting, have typically shown a trend toward improved outcomes, none has set forth clear dosing protocol recommendations for use by practicing physicians. It is our goal in this review of the available literature on the use of IB, as an adjunct to inhaled short-acting beta-adrenergic agonists, to summarize practical, evidence-based recommendations for use in the pediatric emergency department setting for acute asthma exacerbations.

We also hope to better delineate the most effective dosing regimen in those patients who might benefit most from the addition of IB and to explore proposed additional benefits it may have as a modulator of cholinergic-induced effects from high-dose beta-agonist therapy and viral triggers.

---

### Guideline for opioid therapy and chronic noncancer pain [^1126Yzqj]. CMAJ (2017). High credibility.

Regarding the medical management of opioids for pain, especially in the context of non-opioid therapies, the 2017 CMA guidelines recommend optimizing nonpharmacological and nonopioid pharmacological therapies. These should be considered as the first-line treatment in patients with chronic non-cancer pain, rather than initiating a trial of opioids.

---

### SPL drug information for ipratropium bromide [^112344RU]. U.S. Food and Drug Administration. High credibility.

The dosage of ipratropium bromide IN for symptomatic relief of rhinorrhea in adults with the common cold is 2 mcg IN q6–8h for up to 4 days (0.06% spray).

---

### Ipratropium bromide [^111KdrrR]. U.S. Food and Drug Administration (2024). High credibility.

If the nasal tip becomes clogged, remove the clear plastic dust cap and safety clip. Hold the nasal tip under running, warm tap water for about a minute. Dry the nasal tip, reprime the nasal spray pump, and replace the plastic dust cap and safety clip.

- **Caution**: Ipratropium Bromide Nasal Solution, 0.06% is intended to relieve your rhinorrhea (runny nose) with regular use. It is therefore important that you use Ipratropium Bromide Nasal Solution, 0.06% as prescribed by your physician. For most patients, some improvement in runny nose is apparent following the first dose of treatment with Ipratropium Bromide Nasal Solution, 0.06%. Do not use Ipratropium Bromide Nasal Solution, 0.06% for longer than four days for your cold or three weeks for seasonal allergic rhinitis unless instructed by your physician.

- **Precaution**: Do not spray Ipratropium Bromide Nasal Solution, 0.06% in your eyes. Should this occur, immediately flush your eye with cool tap water for several minutes. If you accidentally spray Ipratropium Bromide Nasal Solution, 0.06% in your eyes, you may experience a temporary blurring of vision, visual halos, or colored images in association with red eyes from conjunctival and corneal congestion; development or worsening of narrow-angle glaucoma; pupil dilation; or acute eye pain/discomfort, and increased sensitivity to light, which may last a few hours. Should acute eye pain or blurred vision occur, contact your doctor.

---

### Xodol [^114xhKh7]. U.S. Food and Drug Administration (2012). Low credibility.

Xodol® is indicated for the relief of moderate to moderately severe pain.

---

### Conservative treatment of acute appendicitis: Heresy or an effective and acceptable alternative to surgery [^116Wfnt6]. European Journal of Gastroenterology & Hepatology (2011). Low credibility.

For more than a century, emergency appendectomy has been a 'surgical dogma' in the management of acute appendicitis (AA). During recent decades, however, there is an increasing body of evidence suggesting that selected patients with AA could be treated conservatively. This approach offers several advantages: high success and low recurrence rates, reduced morbidity and mortality, less pain, shorter hospitalization and sick leave, and reduced costs. Although conservative management of AA cannot be used for all patients with AA — such as in the presence of peritonitis — it could be preferred in a large percentage of patients with mild infection, as evidenced by clinical, laboratory, and imaging findings.